BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a hold rating to a buy rating in a research note published on Friday, BidAskClub reports.

Other analysts have also issued research reports about the company. Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating and set a $3.00 target price for the company in a report on Tuesday, June 4th. Barclays lowered Achillion Pharmaceuticals from an equal weight rating to an underweight rating and lowered their target price for the stock from $5.00 to $2.50 in a report on Friday, May 3rd. Finally, ValuEngine upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $2.75.

Achillion Pharmaceuticals stock opened at $4.77 on Friday. The business has a fifty day moving average of $3.53 and a two-hundred day moving average of $3.00. The firm has a market cap of $659.35 million, a P/E ratio of -9.35 and a beta of 1.91. Achillion Pharmaceuticals has a twelve month low of $1.29 and a twelve month high of $5.03.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14). Research analysts anticipate that Achillion Pharmaceuticals will post -0.59 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Achillion Pharmaceuticals by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,257,553 shares of the biopharmaceutical company’s stock valued at $32,851,000 after purchasing an additional 324,147 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Achillion Pharmaceuticals by 3.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 7,442,477 shares of the biopharmaceutical company’s stock valued at $11,833,000 after purchasing an additional 259,762 shares during the last quarter. Mak Capital One LLC lifted its holdings in shares of Achillion Pharmaceuticals by 33.5% during the 1st quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock valued at $20,512,000 after purchasing an additional 1,738,053 shares during the last quarter. UBS Group AG lifted its holdings in shares of Achillion Pharmaceuticals by 48.6% during the 2nd quarter. UBS Group AG now owns 5,575,528 shares of the biopharmaceutical company’s stock valued at $14,942,000 after purchasing an additional 1,824,534 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Achillion Pharmaceuticals by 31.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,007,000 shares of the biopharmaceutical company’s stock valued at $8,059,000 after purchasing an additional 728,000 shares during the last quarter. Hedge funds and other institutional investors own 79.24% of the company’s stock.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Article: What is an investor looking for in an SEC filing?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.